JESSICA GLASSMAN: Open Payments
NPI 1992054183 · MISHAWAKA, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$10,376 in 150 payments from 38 companies in 2025. Trend: 2023 $2,531 · 2024 $3,026 · 2025 $10,376
Food & beverage: $3,763Honoraria: $3,739Speaker / faculty: $1,525Consulting: $1,350
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 9 | $4,030 |
| PFIZER INC. | 11 | $3,267 |
| Vanda Pharmaceuticals Inc. | 11 | $438 |
| ABBVIE INC. | 10 | $304 |
| UCB, Inc. | 12 | $194 |
| Celgene Corporation | 7 | $174 |
| Biogen, Inc. | 8 | $166 |
| ARGENX US, INC. | 6 | $147 |
| JAZZ PHARMACEUTICALS INC. | 4 | $137 |
| Amgen Inc. | 6 | $124 |
Products named: Symbravo, NURTEC ODT, PONVORY, ZAVZPRET, ZEPOSIA, TYSABRI, QULIPTA, EPIDIOLEX.
Industry payments across IN — which companies pay providers there.
